Proteomics International Laboratories Ltd (PIQ.AX)

0.6000 0.0000 (0.00%) At close: 04:10PM AEST

Proteomics International Laboratories Ltd

QEII Medical Centre
QQ Block 6 Verdun Street Nedlands
Perth, WA 6009
Australia
61 8 9389 1992
https://www.proteomics.com.au

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Richard John Lipscombe M.A., MA (Oxford), Ph.D., Ph.D., (London)	Co-Founder, MD & Director	415.35k	N/A	N/A
Ms. Jacqueline Gray	CFO & Head of Corporate Development	259.44k	N/A	N/A
Mr. John Chuck Morrison	Head of Business Development	N/A	N/A	N/A
Dr. Scott Bringans	Head of Research	N/A	N/A	N/A
Dr. Pearl Tan	Head of Product Development	N/A	N/A	N/A
Dr. Kirsten Peters	Head of Clinical Studies	N/A	N/A	N/A
Ms. Karen Teresa Logan ACIS, B.Com., BCom, DipAppCorpGov, F Fin, FCIS, FC	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. It provides PromarkerD, a protein-based diagnostic blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, that has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for diabetic kidney disease in type 1 diabetes; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy; and Giardia, a causing gastroenteritis. The company also offers analytical services, such as pharmacokinetic testing, biomarker discovery, protein analysis, project consultation, and specialist contract research. Proteomics International Laboratories Ltd was founded in 2001 and is headquartered in Perth, Australia.

Corporate governance

Proteomics International Laboratories Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.